Apimeds Pharma Shares Surge 20% After Settlement

Shares of Apimeds Pharma jumped over 20% before a volatility halt after announcing settlement with Inscobee parties resolving merger disputes.
Settlement clears path for completion of the Dec 1 2025 merger with MindWave Innovations and the previously disclosed $100 million PIPE financing.
The deal creates Lōkahi Therapeutics, transfers $4 million to APUS, assigns a $2.2 million CRO credit, and allocates 51% of Lōkahi stock to APUS.
Settlement mandates forming a subsidiary, with 10% of proceeds to it and 90% to MindWave, to be spun off within 12 months.